ArticleCureus2025
Ovarian Cystadenofibroma: An Overview.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background An uncommon benign ovarian tumour with both cystic and solid features has been noted with increasing frequency at our institution. Though often asymptomatic, it can occasionally present with abdominal symptoms or menstrual irregularities. This observation prompted an investigation into the clinical and epidemiological patterns of these cases. Methods This retrospective observational study included 96 cases of ovarian cystadenofibroma operated on between January 2023 and November 2023. Demographic data, clinical presentation, and radiological, intraoperative, and histopathological findings were assessed. Statistical significance was set at p < 0.05. Results Among 96 cases, serous (n = 42, 44%), mucinous (n = 36, 38%), and mixed (n = 18, 19%) subtypes were identified. Statistically significant associations were found between histological subtype and dyslipidaemia (P = 0.0003), heavy menstrual bleeding (P = 0.01), dysmenorrhea (P = 0.03), infertility (P = 0.001), tumour size (P = 0.0001), laterality (P = 0.0001), and torsion (P = 0.03). Mixed tumours in our cohort were larger and more prone to torsion, while serous tumours more frequently showed bilateral involvement. CA-125 levels and IOTA patterns did not show a significant correlation. Conclusion A higher-than-expected number of cystadenofibroma cases were observed in our institution. Although benign, these tumours can present with features that mimic malignancy, potentially leading to aggressive surgical management. Early identification through clinical and radiological correlation in our setting may help reduce overtreatment and guide appropriate surgical planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.